Table 1.
Characteristics | N | Mean OS (months) | X 2 | P value | |
---|---|---|---|---|---|
Age | <65 Y | 87 | 51.5 | 8.3 | 0.004 |
≥65 Y | 243 | 41.7 | |||
| |||||
Sex | Male | 198 | 41 | 6.7 | 0.01 |
Female | 132 | 48.6 | |||
| |||||
Primary site | Rectum | 129 | 47.4 | 2.1 | 0.144 |
Colon | 201 | 42.3 | |||
| |||||
Tumor size | <5 cm | 205 | 44.1 | 0.1 | 0.829 |
5+ cm | 125 | 45 | |||
| |||||
T stage | T0–T2 | 68 | 48.7 | 2.3 | 0.138 |
T3–T4 | 262 | 43.2 | |||
| |||||
N stage | N0 | 185 | 48.5 | 8.9 | 0.003 |
N1–N3 | 145 | 38.7 | |||
| |||||
M stage | M0 | 275 | 46.9 | 17.9 | <0.001 |
M1 | 55 | 30.7 | |||
| |||||
Stage | I-II | 163 | 49.2 | 9.1 | 0.003 |
III-IV | 167 | 39.2 | |||
| |||||
NLR | <3.03 (low) | 176 | 49.7 | 16.6 | <0.001 |
≥3.03 (high) | 154 | 37.4 | |||
| |||||
PLR | <149.73 (low) | 148 | 49.2 | 9.7 | 0.002 |
≥149.73 (high) | 182 | 40.2 | |||
| |||||
CEA (ng/mL) | <13.4 (low) | 244 | 47.9 | 17.9 | <0.001 |
≥13.4 (high) | 86 | 33.3 | |||
| |||||
CEA + NLR | Low | 141 | 52.6 | 24.4 | <0.001 |
High | 189 | 37.4 | |||
| |||||
CEA + PLR | Low | 117 | 51.6 | 13.4 | <0.001 |
High | 213 | 40.4 | |||
| |||||
NLR + PLR | Low | 116 | 52 | 15.5 | <0.001 |
High | 214 | 40 | |||
| |||||
CEA + NLR + PLR | Low | 94 | 54.7 | 19.3 | <0.001 |
High | 236 | 40.2 | |||
| |||||
BMI | <21.7 (low) | 155 | 35.1 | 35.5 | <0.001 |
≥21.7 (high) | 175 | 52.3 |
NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; CEA, carcinoembryonic antigen; BMI, body mass index.